Literature DB >> 9182250

Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.

T Nakajima1.   

Abstract

The particulars regarding the amine precursor therapy for treatment of neuropsychiatric disorders and their neurochemical background are described historically. Furthermore, peculiar or artificial amino acids which are metabolized into the brain amine or their derivatives and promised their clinical application are also introduced.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9182250     DOI： 10.1007/BF02529142

Source DB:  PubMed          Journal:  Neurochem Res        ISSN： 0364-3190            Impact factor:   3.996


  31 in total

1.  INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM.

Authors:  L J POIRIER; T L SOURKES
Journal:  Brain       Date:  1965-03       Impact factor: 13.501

2.  Effects of 3,4-dihydroxyphenylserine on the concentration of brain noradrenaline and the level of plasma growth hormone of rats.

Authors:  M Hirai; Y Matsuoka; T Nakajima; I Sano
Journal:  Med J Osaka Univ       Date:  1975-09

3.  The formation in vivo of noradrenaline from 3:4-dihydroxyphenylserine (noradrenaline carboxylic acid).

Authors:  C G SCHMITERLOW
Journal:  Br J Pharmacol Chemother       Date:  1951-03

4.  Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.

Authors:  T N Chase
Journal:  Neurology       Date:  1970-12       Impact factor: 9.910

5.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

6.  Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug.

Authors:  T Nakajima; Y Kudo; Z Kaneko
Journal:  Folia Psychiatr Neurol Jpn       Date:  1978

7.  D-phenylalanine in endogenous depression.

Authors:  J Mann; E D Peselow; S Snyderman; S Gershon
Journal:  Am J Psychiatry       Date:  1980-12       Impact factor: 18.112

8.  Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.

Authors:  T Nagatsu; T Kato; Y Numata; K Ikuta; M Sano
Journal:  Clin Chim Acta       Date:  1977-03-01       Impact factor: 3.786

9.  Effects of L-erythro-3, 4-dihydroxyphenylserine on sleep-wakefulness patterns and concentrations of brain catecholamines and serotonin in rats.

Authors:  M Mori; H Hashimoto; K Fukui; T Mori; T Noto; T Nakajima
Journal:  Jpn J Psychiatry Neurol       Date:  1987-06

10.  (S)-norepinephrine in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS).

Authors:  C C Porter; M L Torchiana; C A Stone
Journal:  Life Sci I       Date:  1972-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.